Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
President Trump is likely to embrace the Medicare drug price negotiations that was initiated under the Biden administration, though the president could make some tweaks to put his own spin on it. The ...
We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...
The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...
CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be ...
Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...
President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation ...
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
The root of the U.S.’s high prescription drug prices lies in its unique system, which allows pharmaceutical manufacturers to ...
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.